Literature DB >> 12623947

Myocardial uptake and biochemical and hemodynamic effects of ACE inhibitors in humans.

Christopher J Zeitz1, Duncan J Campbell, John D Horowitz.   

Abstract

There is little information on the processes affecting selective tissue ACE inhibition and the implications in human subjects. We compared intravenously administered ACE inhibitors, perindoprilat and enalaprilat, for myocardial drug uptake and effects on angiotensin and bradykinin peptides versus hemodynamic effects in 25 patients with stable angina and well-preserved left ventricular systolic function. Myocardial uptake was rapid and more efficient for perindoprilat than for enalaprilat (peak content at 26+/-3 and 30+/-4 seconds, 0.58+/-0.12% and 0.27+/-0.07% of the administered dose for perindoprilat and enalaprilat, respectively, P=0.04 for difference). Both drugs caused a decrease in angiotensin (Ang) II level, an increase in Ang I level, and reduction in Ang II/Ang I ratio in arterial and coronary sinus blood. Bradykinin (BK)-(1-9) and BK-(1-8) levels increased in arterial blood and BK-(1-8) levels increased in coronary sinus blood after drug administration. Perindoprilat and enalaprilat caused a small decrease in mean arterial pressure (-3+/-1%, P<0.05; and -4+/-1%, P<0.01, respectively) and LV+dP/dt (-5.8+/-1.7%, P<0.01 and -4.2+/-2.8%, P<0.05, respectively), whereas systemic vascular resistance index was unchanged. Despite relatively cardioselective uptake of perindoprilat, both drugs had similar effects on the cardiac metabolism of angiotensin and bradykinin and on cardiac function. Under resting conditions, both drugs exerted small negative inotropic effects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12623947     DOI: 10.1161/01.HYP.0000054976.67487.08

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  8 in total

1.  Increased tissue kallikrein levels in type 2 diabetes.

Authors:  D J Campbell; A Kladis; Y Zhang; A J Jenkins; D L Prior; M Yii; J F Kenny; M J Black; D J Kelly
Journal:  Diabetologia       Date:  2010-01-10       Impact factor: 10.122

2.  Genetic models provide unique insight into angiotensin and bradykinin peptides in the extravascular compartment of the heart in vivo.

Authors:  Duncan J Campbell; Hong D Xiao; Sebastien Fuchs; Kenneth E Bernstein
Journal:  Clin Exp Pharmacol Physiol       Date:  2008-10-28       Impact factor: 2.557

Review 3.  The kallikrein-kinin system in diabetic nephropathy.

Authors:  Hirofumi Tomita; Ryan B Sanford; Oliver Smithies; Masao Kakoki
Journal:  Kidney Int       Date:  2012-02-08       Impact factor: 10.612

4.  Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat.

Authors:  David G Levitt; Rik C Schoemaker
Journal:  BMC Clin Pharmacol       Date:  2006-01-06

Review 5.  A review of Perindopril in the reduction of cardiovascular events.

Authors:  Duncan J Campbell
Journal:  Vasc Health Risk Manag       Date:  2006

6.  Plasma bradykinin and early diabetic nephropathy lesions in type 1 diabetes mellitus.

Authors:  Kevin M Wheelock; Jian Cai; Helen C Looker; Michael L Merchant; Robert G Nelson; Gudeta D Fufaa; E Jennifer Weil; Harold I Feldman; Ramachandran S Vasan; Paul L Kimmel; Brad H Rovin; Michael Mauer; Jon B Klein
Journal:  PLoS One       Date:  2017-07-10       Impact factor: 3.240

Review 7.  Neprilysin Inhibitors and Bradykinin.

Authors:  Duncan J Campbell
Journal:  Front Med (Lausanne)       Date:  2018-09-19

Review 8.  Clinical relevance of local Renin Angiotensin systems.

Authors:  Duncan J Campbell
Journal:  Front Endocrinol (Lausanne)       Date:  2014-07-14       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.